OKT3 prophylaxis in renal grafts with prolonged cold ischemia times

Association with improvement in long-term survival

Daniel Abramowicz, Douglas Norman, Pierre Vereerstraeten, Michel Goldman, Luc De Pauw, Jean Louis Vanherweghem, Paul Kinnaert, Lawrence Kahana, Frank P. Stuart, James R. Thistlethwaite, Charles F. Shield, Anthony Monaco, Shu Chen Wu, Thomas P. Haverty

Research output: Contribution to journalArticle

41 Citations (Scopus)

Abstract

The data on patients participating in two randomized, prospective studies with similar immunosuppressive regimens were updated and combined to evaluate the long-term effects of OKT3 according to cold ischemia lime (≤ or > 24 hr). Among 159 patients in the OKT3 and 153 in the cyclosporine A (CsA) group, 8 and 12 deaths occurred, respectively (P = NS). In patients with cold ischemia > 24 hours, OKT3 prophylaxis resulted in a lower mean number of rejection episodes per patient than did CsA prophylaxis within one year (mean ± SEM: 0.87 ± 0.11 vs. 1.35 ± 0.14, respectively; P = 0.008) and within five years (1.07 ± 0.12 vs. 1.49 ± 0.15, respectively; P = 0.032). In contrast, rejection incidences in patients with cold ischemia ≤ 24 hours was not significantly different in the two groups. In all study patients, there was a trend towards higher graft survival rates in the OKT3 group versus the CsA group (at 5 years, 73% vs. 66%, respectively; P = 0.182). Among recipients of kidneys with cold ischemia times > 24 hours, OKT3 patients had significantly higher graft survival than CsA patients at two years (84% vs. 64%, respectively) and at five years (71% vs. 56%, respectively; P = 0.045). Significant differences were not observed in recipients of kidneys with cold ischemia times ≤ 24 hours. In conclusion, patients receiving renal grafts with long cold ischemia times strongly benefit from OKT3 prophylaxis.

Original languageEnglish (US)
Pages (from-to)768-772
Number of pages5
JournalKidney International
Volume49
Issue number3
StatePublished - 1996
Externally publishedYes

Fingerprint

Cold Ischemia
Muromonab-CD3
Transplants
Kidney
Survival
Cyclosporine
Graft Survival
Immunosuppressive Agents
Survival Rate
Prospective Studies

ASJC Scopus subject areas

  • Nephrology

Cite this

Abramowicz, D., Norman, D., Vereerstraeten, P., Goldman, M., De Pauw, L., Vanherweghem, J. L., ... Haverty, T. P. (1996). OKT3 prophylaxis in renal grafts with prolonged cold ischemia times: Association with improvement in long-term survival. Kidney International, 49(3), 768-772.

OKT3 prophylaxis in renal grafts with prolonged cold ischemia times : Association with improvement in long-term survival. / Abramowicz, Daniel; Norman, Douglas; Vereerstraeten, Pierre; Goldman, Michel; De Pauw, Luc; Vanherweghem, Jean Louis; Kinnaert, Paul; Kahana, Lawrence; Stuart, Frank P.; Thistlethwaite, James R.; Shield, Charles F.; Monaco, Anthony; Wu, Shu Chen; Haverty, Thomas P.

In: Kidney International, Vol. 49, No. 3, 1996, p. 768-772.

Research output: Contribution to journalArticle

Abramowicz, D, Norman, D, Vereerstraeten, P, Goldman, M, De Pauw, L, Vanherweghem, JL, Kinnaert, P, Kahana, L, Stuart, FP, Thistlethwaite, JR, Shield, CF, Monaco, A, Wu, SC & Haverty, TP 1996, 'OKT3 prophylaxis in renal grafts with prolonged cold ischemia times: Association with improvement in long-term survival', Kidney International, vol. 49, no. 3, pp. 768-772.
Abramowicz D, Norman D, Vereerstraeten P, Goldman M, De Pauw L, Vanherweghem JL et al. OKT3 prophylaxis in renal grafts with prolonged cold ischemia times: Association with improvement in long-term survival. Kidney International. 1996;49(3):768-772.
Abramowicz, Daniel ; Norman, Douglas ; Vereerstraeten, Pierre ; Goldman, Michel ; De Pauw, Luc ; Vanherweghem, Jean Louis ; Kinnaert, Paul ; Kahana, Lawrence ; Stuart, Frank P. ; Thistlethwaite, James R. ; Shield, Charles F. ; Monaco, Anthony ; Wu, Shu Chen ; Haverty, Thomas P. / OKT3 prophylaxis in renal grafts with prolonged cold ischemia times : Association with improvement in long-term survival. In: Kidney International. 1996 ; Vol. 49, No. 3. pp. 768-772.
@article{b8d689e482194d6fa604f121d2f26400,
title = "OKT3 prophylaxis in renal grafts with prolonged cold ischemia times: Association with improvement in long-term survival",
abstract = "The data on patients participating in two randomized, prospective studies with similar immunosuppressive regimens were updated and combined to evaluate the long-term effects of OKT3 according to cold ischemia lime (≤ or > 24 hr). Among 159 patients in the OKT3 and 153 in the cyclosporine A (CsA) group, 8 and 12 deaths occurred, respectively (P = NS). In patients with cold ischemia > 24 hours, OKT3 prophylaxis resulted in a lower mean number of rejection episodes per patient than did CsA prophylaxis within one year (mean ± SEM: 0.87 ± 0.11 vs. 1.35 ± 0.14, respectively; P = 0.008) and within five years (1.07 ± 0.12 vs. 1.49 ± 0.15, respectively; P = 0.032). In contrast, rejection incidences in patients with cold ischemia ≤ 24 hours was not significantly different in the two groups. In all study patients, there was a trend towards higher graft survival rates in the OKT3 group versus the CsA group (at 5 years, 73{\%} vs. 66{\%}, respectively; P = 0.182). Among recipients of kidneys with cold ischemia times > 24 hours, OKT3 patients had significantly higher graft survival than CsA patients at two years (84{\%} vs. 64{\%}, respectively) and at five years (71{\%} vs. 56{\%}, respectively; P = 0.045). Significant differences were not observed in recipients of kidneys with cold ischemia times ≤ 24 hours. In conclusion, patients receiving renal grafts with long cold ischemia times strongly benefit from OKT3 prophylaxis.",
author = "Daniel Abramowicz and Douglas Norman and Pierre Vereerstraeten and Michel Goldman and {De Pauw}, Luc and Vanherweghem, {Jean Louis} and Paul Kinnaert and Lawrence Kahana and Stuart, {Frank P.} and Thistlethwaite, {James R.} and Shield, {Charles F.} and Anthony Monaco and Wu, {Shu Chen} and Haverty, {Thomas P.}",
year = "1996",
language = "English (US)",
volume = "49",
pages = "768--772",
journal = "Kidney International",
issn = "0085-2538",
publisher = "Nature Publishing Group",
number = "3",

}

TY - JOUR

T1 - OKT3 prophylaxis in renal grafts with prolonged cold ischemia times

T2 - Association with improvement in long-term survival

AU - Abramowicz, Daniel

AU - Norman, Douglas

AU - Vereerstraeten, Pierre

AU - Goldman, Michel

AU - De Pauw, Luc

AU - Vanherweghem, Jean Louis

AU - Kinnaert, Paul

AU - Kahana, Lawrence

AU - Stuart, Frank P.

AU - Thistlethwaite, James R.

AU - Shield, Charles F.

AU - Monaco, Anthony

AU - Wu, Shu Chen

AU - Haverty, Thomas P.

PY - 1996

Y1 - 1996

N2 - The data on patients participating in two randomized, prospective studies with similar immunosuppressive regimens were updated and combined to evaluate the long-term effects of OKT3 according to cold ischemia lime (≤ or > 24 hr). Among 159 patients in the OKT3 and 153 in the cyclosporine A (CsA) group, 8 and 12 deaths occurred, respectively (P = NS). In patients with cold ischemia > 24 hours, OKT3 prophylaxis resulted in a lower mean number of rejection episodes per patient than did CsA prophylaxis within one year (mean ± SEM: 0.87 ± 0.11 vs. 1.35 ± 0.14, respectively; P = 0.008) and within five years (1.07 ± 0.12 vs. 1.49 ± 0.15, respectively; P = 0.032). In contrast, rejection incidences in patients with cold ischemia ≤ 24 hours was not significantly different in the two groups. In all study patients, there was a trend towards higher graft survival rates in the OKT3 group versus the CsA group (at 5 years, 73% vs. 66%, respectively; P = 0.182). Among recipients of kidneys with cold ischemia times > 24 hours, OKT3 patients had significantly higher graft survival than CsA patients at two years (84% vs. 64%, respectively) and at five years (71% vs. 56%, respectively; P = 0.045). Significant differences were not observed in recipients of kidneys with cold ischemia times ≤ 24 hours. In conclusion, patients receiving renal grafts with long cold ischemia times strongly benefit from OKT3 prophylaxis.

AB - The data on patients participating in two randomized, prospective studies with similar immunosuppressive regimens were updated and combined to evaluate the long-term effects of OKT3 according to cold ischemia lime (≤ or > 24 hr). Among 159 patients in the OKT3 and 153 in the cyclosporine A (CsA) group, 8 and 12 deaths occurred, respectively (P = NS). In patients with cold ischemia > 24 hours, OKT3 prophylaxis resulted in a lower mean number of rejection episodes per patient than did CsA prophylaxis within one year (mean ± SEM: 0.87 ± 0.11 vs. 1.35 ± 0.14, respectively; P = 0.008) and within five years (1.07 ± 0.12 vs. 1.49 ± 0.15, respectively; P = 0.032). In contrast, rejection incidences in patients with cold ischemia ≤ 24 hours was not significantly different in the two groups. In all study patients, there was a trend towards higher graft survival rates in the OKT3 group versus the CsA group (at 5 years, 73% vs. 66%, respectively; P = 0.182). Among recipients of kidneys with cold ischemia times > 24 hours, OKT3 patients had significantly higher graft survival than CsA patients at two years (84% vs. 64%, respectively) and at five years (71% vs. 56%, respectively; P = 0.045). Significant differences were not observed in recipients of kidneys with cold ischemia times ≤ 24 hours. In conclusion, patients receiving renal grafts with long cold ischemia times strongly benefit from OKT3 prophylaxis.

UR - http://www.scopus.com/inward/record.url?scp=9044225150&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=9044225150&partnerID=8YFLogxK

M3 - Article

VL - 49

SP - 768

EP - 772

JO - Kidney International

JF - Kidney International

SN - 0085-2538

IS - 3

ER -